Archive: 18/08/2016
Nivolumab in advanced lung cancer: Indication of major added benefit
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
Brivaracetam in epilepsy: Added benefit still not proven
Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adults and adolescents from 16 years of age with epileptic seizures. The German Institute for Quality and Efficiency in Health ...
Aug 18, 2016
Postoperative telephone clinic can be used in lieu of in-person care for some patients
Implementation of a telephone postoperative clinic at a Veterans Affairs facility significantly improved utilization of surgeon and facility resources while maintaining satisfactory patient outcomes, according to study results ...
Aug 18, 2016
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
The drug combination emtricitabine/tenofovir alafenamide is approved in combination with other antiviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1). In an ...
Aug 18, 2016
Ramucirumab in stomach cancer: Added benefit not proven
Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called ...
Aug 18, 2016
New report presents bundled payment model for breast cancer screening
According to a new report by the Harvey L. Neiman Health Policy Institute, mammography may present an opportunity for the expanded use of bundled payments in radiology. The study, published online in the Journal of the American ...
Aug 18, 2016